AGRX Agile Therapeutics Inc.

3.04
-0.07  -2%
Previous Close 3.11
Open 3.11
52 Week Low 0.35
52 Week High 4.7652
Market Cap $265,384,719
Shares 87,297,605
Float 70,805,390
Enterprise Value $176,547,198
Volume 946,134
Av. Daily Volume 1,420,691
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Twirla
Contraceptive patch
Approved
Approved
FDA Approval announced February 14, 2020.

Latest News

  1. PRINCETON, N.J., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be virtually presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 23, 2020 at 3:20 PM EDT.

    A live webcast of the presentation will be available in the Events and Presentations section of the Investor Relations page or by clicking here. The archived webcast will be available on the Company's website for 30 days.

    About Agile Therapeutics, Inc.
    Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today's women.  Our product candidates are designed to provide women with…

    PRINCETON, N.J., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be virtually presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 23, 2020 at 3:20 PM EDT.

    A live webcast of the presentation will be available in the Events and Presentations section of the Investor Relations page or by clicking here. The archived webcast will be available on the Company's website for 30 days.

    About Agile Therapeutics, Inc.

    Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today's women.  Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.  Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company's website.

    Follow Agile on LinkedIn and Twitter: @AgileTher.

    Contact:  

    Matt Riley

    Head of Investor Relations & Corporate Communications

    Primary Logo

    View Full Article Hide Full Article
  2. PRINCETON, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a forward-thinking women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on Wednesday, September 16, 2020 at 11:30 a.m. EDT.

    A live webcast of the fireside chat will be available in the Events and Presentations section of the Investor Relations page or by clicking here. The archived webcast will be available on the Company's website for 30 days.

    About Agile Therapeutics, Inc.
    Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today's women.  Our product…

    PRINCETON, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a forward-thinking women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on Wednesday, September 16, 2020 at 11:30 a.m. EDT.

    A live webcast of the fireside chat will be available in the Events and Presentations section of the Investor Relations page or by clicking here. The archived webcast will be available on the Company's website for 30 days.

    About Agile Therapeutics, Inc.

    Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today's women.  Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.  Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company's website.

    Follow Agile on LinkedIn and Twitter: @AgileTher.

    Contact: 

    Matt Riley

    Head of Investor Relations & Corporate Communications

     

    Primary Logo

    View Full Article Hide Full Article
  3. Company to Present Twirla® Commercial Plan

    Webcast Scheduled from 11:00 am – 1:00 pm EDT

    PRINCETON, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that it will host a virtual Investor/Analyst Day on Monday, September 21, 2020 from 11:00 AM to 1:00 PM EDT.

    Members of the Agile Therapeutics senior management team and an industry key opinion leader will provide an overview of the Twirla® commercial program, including planned launch activities, marketing initiatives and managed care strategy.

    Scheduled speakers include:

    • Al Altomari, Agile Therapeutics Chairman and Chief Executive Officer
    • Dennis Reilly, Agile Therapeutics Senior Vice President and Chief Financial…

    Company to Present Twirla® Commercial Plan

    Webcast Scheduled from 11:00 am – 1:00 pm EDT

    PRINCETON, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that it will host a virtual Investor/Analyst Day on Monday, September 21, 2020 from 11:00 AM to 1:00 PM EDT.

    Members of the Agile Therapeutics senior management team and an industry key opinion leader will provide an overview of the Twirla® commercial program, including planned launch activities, marketing initiatives and managed care strategy.

    Scheduled speakers include:

    • Al Altomari, Agile Therapeutics Chairman and Chief Executive Officer
    • Dennis Reilly, Agile Therapeutics Senior Vice President and Chief Financial Officer
    • Kimberly Whelan, Agile Therapeutics Vice President of Sales and Market Access
    • Amy Welsh, Agile Therapeutics Vice President of Marketing
    • Dr. David Portman, MD, FACOG, OB/GYN and Agile Therapeutics Consultant

    Those interested in attending can click the RSVP link in the Events & Presentations page of the ‘Investors' section of the Agile Therapeutics website or by clicking here.

    A live audio webcast of the presentation with accompanying slides can be accessed by visiting ir.agiletherapeutics.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the Company's website for 30 days.

    About Agile Therapeutics, Inc.

    Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company's website.

    Follow Agile on LinkedIn and Twitter: @AgileTher.

    Contact: 

    Matt Riley

    Head of Investor Relations & Corporate Communications

    Primary Logo

    View Full Article Hide Full Article
  4. Visit BirthControlDoneMyWay.com to learn more about some of the many available contraceptive options

    • I'm So Done is a national unbranded campaign intended to enhance the birth control conversation for women
    • Encourage education on contraceptive care options
    • Facilitate an honest discussion between women and their healthcare providers  
    • Spark a social community of likeminded women in the "So Done Club," reassuring them that they are not alone
    • Join the conversation by participating on social media platforms, including the @SoDoneClub Facebook and Instagram pages

    PRINCETON, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a forward-thinking women's healthcare company, today announced the launch of I'm So Done, an education…

    Visit BirthControlDoneMyWay.com to learn more about some of the many available contraceptive options

    • I'm So Done is a national unbranded campaign intended to enhance the birth control conversation for women
    • Encourage education on contraceptive care options
    • Facilitate an honest discussion between women and their healthcare providers  
    • Spark a social community of likeminded women in the "So Done Club," reassuring them that they are not alone
    • Join the conversation by participating on social media platforms, including the @SoDoneClub Facebook and Instagram pages

    PRINCETON, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a forward-thinking women's healthcare company, today announced the launch of I'm So Done, an education and empowerment platform that encourages women to think about their current contraceptive method and decision-making journey.

    "We are excited to launch I'm So Done, a new digital-first campaign to help women recognize that they have the right to be an active participant in selecting contraceptive care that suits their lifestyle," said Al Altomari, Chairman and Chief Executive Officer of Agile Therapeutics.

    Agile Therapeutics Vice President of Marketing Amy Welsh added, "We believe that finding the right contraceptive method is an important factor in sexual and reproductive health. Yet, despite the availability of a wide range of birth control options, many women struggle to determine which method is the best fit for them. I'm So Done will provide education and encouragement for women to take a more empowered and informed role in shared decision-making with her healthcare provider about birth control."

    I'm So Done features a balanced discussion of the spectrum of contraceptive methods, helping women to explore their options. The campaign is designed to encourage a two-way dialogue between women and their healthcare providers about sexual health as well as contraceptive practices and concerns. In addition to education, I'm So Done provides a safe place for women to discuss their experiences, with the reassurance that they are not alone, on the @SoDoneClub Facebook and Instagram pages.

    "Women stay on a method longer if it is a method of their choosing and contraceptive education is critical to informing choice," said Deborah Arrindell, VP of Health Policy at the American Sexual Health Association. "According to the Guttmacher Institute, a woman who wants two children will use contraception for about three decades. Women need different options throughout their lives, and we welcome a platform like I'm So Done to help women learn about contraceptive choice for their lifestyle."

    Visit BirthControlDoneMyWay.com to see how real women are responding to a poll about birth control, and to find helpful information and tools outlining the pros and cons of various contraceptive methods. 

    About Agile Therapeutics, Inc.

    Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company's website.

    Follow Agile on LinkedIn and Twitter: @AgileTher.

    Source: Agile Therapeutics

    Contact: 

    Matt Riley

    Head of Investor Relations & Corporate Communications

     

    Photos accompanying this announcement are available at:

    https://www.globenewswire.com/NewsRoom/AttachmentNg/7fb10a4e-a77d-42df-8d4e-96915ea04c40

    https://www.globenewswire.com/NewsRoom/AttachmentNg/886f9d45-2994-4ea3-a814-1ae0e4d062a9

    Primary Logo

    View Full Article Hide Full Article
  5. PRINCETON, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a forward-thinking women's healthcare company, today announced the appointment of Paul Korner, MD, MBA, to the position of Chief Medical Officer. Dr. Korner is a board-certified obstetrician and gynecologist with more than 20 years of pharmaceutical and biotech industry experience, including significant experience within women's healthcare. He will be responsible for supporting the commercial launch of Twirla®, advancing the Company's internal pipeline and evaluating external growth opportunities. Dr. Korner will report to Al Altomari, Agile's Chairman and Chief Executive Officer.

    "We are excited to welcome Dr. Korner to Agile as we continue to strengthen…

    PRINCETON, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a forward-thinking women's healthcare company, today announced the appointment of Paul Korner, MD, MBA, to the position of Chief Medical Officer. Dr. Korner is a board-certified obstetrician and gynecologist with more than 20 years of pharmaceutical and biotech industry experience, including significant experience within women's healthcare. He will be responsible for supporting the commercial launch of Twirla®, advancing the Company's internal pipeline and evaluating external growth opportunities. Dr. Korner will report to Al Altomari, Agile's Chairman and Chief Executive Officer.

    "We are excited to welcome Dr. Korner to Agile as we continue to strengthen and expand our senior leadership team," said Al Altomari. "Dr. Korner's private practice work and his deep pharmaceutical experience, particularly in leading multiple women's health product approvals and launches, makes him a natural fit as we continue to advance Twirla towards commercial launch and broaden our women's health portfolio for areas of unmet need."

    Dr. Korner has served in various leadership positions of increasing responsibility at several global companies focused on female reproductive health, including Solvay Pharmaceuticals, Wyeth Research, Bayer, and Ferring Pharmaceuticals. Dr. Korner has led more than 50 clinical trials that include multiple engagements with the U.S. Food and Drug Administration, European Medicines Agency, Pharmaceuticals and Medical Devices Agency in Japan, and Health Canada.   Most recently Dr. Korner brought his clinical and development acumen to the gene therapy space as a Senior Vice President of Clinical Development & Medical Affairs at Axovant Gene Therapies, Ltd.

    "Agile is at the forefront of expanding healthcare options for women, and I am thrilled to join the Company at this important time. I look forward to supporting Agile's continued product development and the launch of Twirla, an innovative and important new contraceptive option for women," said Dr. Korner.

    Dr. Korner received his MD from the Stritch School of Medicine at Loyola University. He also holds an MBA from the Michael J. Coles College of Business at Kennesaw State University. He currently serves on the Laidlaw Venture Partners Scientific Advisory Board and the Board of Directors of Voltron Therapeutics as an Independent Director.

    About Agile Therapeutics, Inc.

    Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today's women.  Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.  Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company's website.

    Follow Agile on LinkedIn and Twitter: @AgileTher.

    Contact: 

    Matt Riley

    Head of Investor Relations & Corporate Communications

    Primary Logo

    View Full Article Hide Full Article
View All Agile Therapeutics Inc. News